Orchestra BioMed Surpasses Enrollment Target in Pivotal BACKBEAT Trial
OBIO has more than doubled off its 52-week low of $2.4.
Summary
Orchestra BioMed has exceeded full enrollment in its BACKBEAT pivotal trial, randomizing 330 patients against a target of 316 across 81 sites in 13 countries. This milestone de-risks the timeline for the AVIM Therapy data readout, now expected next spring. The trial, run with Medtronic, is testing whether pacemaker-based AVIM Therapy can lower blood pressure in patients with uncontrolled hypertension. Positive results could unlock a large market opportunity and trigger regulatory submissions. The company's cash runway extends into late 2027, providing funding through the data readout.
At the time of this announcement, OBIO was trading at $6.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.9M. The 52-week trading range was $2.40 to $6.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.